Similar articles

• Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.

  Goldschmidt-Clermont PJ. Goldschmidt-Clermont PJ. J Invasive Cardiol. 2002 Dec;14 Suppl E:1E. J Invasive Cardiol. 2002. PMID: 12668856 No abstract available.
• Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

  Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ. Lincoff AM, et al. N Engl J Med. 1999 Jul 29;341(5):319-27. doi: 10.1056/NEJM199907293410503. N Engl J Med. 1999. PMID: 10423466 Clinical Trial.
• IIb/IIIa platelet inhibitors in the management of coronary artery disease.

  Talley JD. Talley JD. J Ark Med Soc. 1996 Oct;93(5):237-9. J Ark Med Soc. 1996. PMID: 8908943 Review. No abstract available.
• [Glycoprotein IIb/IIIa antagonists].

  Hennemann A. Hennemann A. Med Monatsschr Pharm. 2000 Dec;23(12):385-90. Med Monatsschr Pharm. 2000. PMID: 11147193 Review. German. No abstract available.
• [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].

  [No authors listed] [No authors listed] Internist (Berl). 1998 Dec;39(12 Suppl Plattchena):1-4. Internist (Berl). 1998. PMID: 10101692 Clinical Trial. German. No abstract available.